Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement.
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Databases, Factual
Delayed Diagnosis
Female
Heart Failure
/ complications
Humans
Immunoglobulin Light-chain Amyloidosis
/ complications
Male
Middle Aged
Prognosis
Retrospective Studies
Surveys and Questionnaires
Survival Analysis
Time-to-Treatment
/ statistics & numerical data
Treatment Outcome
AL amyloidosis
awareness
late diagnosis
overall survival
treatment outcome
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
revised:
23
06
2021
received:
18
04
2021
accepted:
24
06
2021
pubmed:
30
6
2021
medline:
20
1
2022
entrez:
29
6
2021
Statut:
ppublish
Résumé
To study the impact of time to diagnosis on cardiac Mayo stages, treatment outcome, and overall survival. We retrospectively analyzed 77 consecutive patients diagnosed between 2015 and 2020 with AL amyloidosis and cardiac involvement. Medical history was recorded in standardized form with the help of a questionnaire. Time from onset of symptoms of cardiac failure to diagnosis was correlated with the severity of cardiac involvement in modified Mayo 2004 and revised Mayo 2012 staging systems (r Sensitizing physicians and raising awareness for the disease are crucial for timely diagnosis and may improve the outcome of the disease.
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
449-457Informations de copyright
© 2021 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.
Références
Falk RH, Comenzo RL, Skinner M. The systemic amyloidosis. NEJM. 1997;337(13):898-909.
Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583-596. https://doi.org/10.1056/NEJMra023144
Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387(10038):2641-2654. https://doi.org/10.1016/S0140-6736(15)01274-X
Rajkumar SV, Gertz MA, Kyle RA. Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer. 1998;82(8):1501-1505.
Zanwar S, Abeykoon JP, Ansell SM, et al. Primary systemic amyloidosis in patients with Waldenstrom macroglobulinemia. Leukemia. 2019;33(3):790-794. https://doi.org/10.1038/s41375-018-0286-7
Sanchorawala V, Blanchard E, Seldin DC, O'Hara C, Skinner M, Wright DG. AL amyloidosis associated with B-cell lymphoproliferative disorders: frequency and treatment outcomes. Am J Hematol. 2006;81(9):692-695. https://doi.org/10.1002/ajh.20635
Gertz MA. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment. Am J Hematol. 2014;89(12):1132-1140. https://doi.org/10.1002/ajh.23828
McCausland KL, White MK, Guthrie SD, et al. Light chain (AL) amyloidosis: the journey to diagnosis. Patient. 2018;11(2):207-216. https://doi.org/10.1007/s40271-017-0273-5
Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29(14):1924-1933. https://doi.org/10.1200/JCO.2010.32.2271
Varga C, Comenzo RL. High-dose melphalan and stem cell transplantation in systemic AL amyloidosis in the era of novel anti-plasma cell therapy: a comprehensive review. Bone Marrow Transplant. 2019;54(4):508-518. https://doi.org/10.1038/s41409-018-0284-4
Quock TP, Yan T, Chang E, Guthrie S, Broder MS. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018;2(10):1046-1053. https://doi.org/10.1182/bloodadvances.2018016402
Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989-995. https://doi.org/10.1200/JCO.2011.38.5724
Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751-3757. https://doi.org/10.1200/JCO.2004.03.029
Wechalekar AD, Schonland SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121(17):3420-3427. https://doi.org/10.1182/blood-2012-12-473066
Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3-9. https://doi.org/10.1038/leu.2008.291
Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541-4549. https://doi.org/10.1200/JCO.2011.37.7614
Palladini G, Schonland SO, Sanchorawala V, et al. Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. Amyloid. 2021;28:1-2. https://doi.org/10.1080/13506129.2020.1868810
Milani P, Basset M, Russo F, Foli A, Merlini G, Palladini G. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. Blood. 2017;130(5):625-631. https://doi.org/10.1182/blood-2017-02-767467
Dittrich T, Bochtler T, Kimmich C, et al. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis. Blood. 2017;130(5):632-642. https://doi.org/10.1182/blood-2017-02-767475
Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79(4):319-328. https://doi.org/10.1002/ajh.20381
Palladini G, Barassi A, Klersy C, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood. 2010;116(18):3426-3430. https://doi.org/10.1182/blood-2010-05-286567
Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis? Blood. 2016;128(2):159-168. https://doi.org/10.1182/blood-2016-01-629790
Schulman A, Connors LH, Weinberg J, et al. Patient outcomes in light chain (AL) amyloidosis: The clock is ticking from symptoms to diagnosis. Eur J Haematol. 2020;105(4):495-501. https://doi.org/10.1111/ejh.13472
Lilleness B, Ruberg FL, Mussinelli R, Doros G, Sanchorawala V. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood. 2019;133(3):215-223. https://doi.org/10.1182/blood-2018-06-858951
Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light chain amyloidosis: patient experience survey from the amyloidosis research consortium. Adv Ther. 2015;32(10):920-928. https://doi.org/10.1007/s12325-015-0250-0
Kourelis TV, Kumar SK, Go RS, et al. Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. Am J Hematol. 2014;89(11):1051-1054. https://doi.org/10.1002/ajh.23827
Sidana S, Tandon N, Gertz MA, et al. Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis. Br J Haematol. 2019;185(4):701-707. https://doi.org/10.1111/bjh.15832